CSV April 4, 2023 through April 4, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PRAVASTATIN ADDITIONAL R		*USP43–NF38*	3645	29-May-2020	1-Jun-2020	*NA*	*NA*	In *USP*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM	EQUIREMENTS							*Reference Standards <11>/USP Pravastatin Related Compound A RS*: Change 446.51 to: 446.52
FILGRASTIM	IDENTIFICATION/*C. Peptide Mapping*	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Standard solution*: Change Prepare a solution containing 80 µg of and 200 µL of *Digestion solution* to: Prepare a solution containing 80 µg of USP Filgrastim RS and 200 µL of *Digestion solution* AND In *System suitability*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								requirements: Change Eight major peaks should be present in each chromatogram as illustrated in the reference chromatogram provided with . to: Eight major peaks should be present in each chromatogram as illustrated in the reference chromatogram provided with USP Filgrastim RS.
ROPIVACAINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS	*USP43–NF38*	3943	29-May-2020	1-Jun-2020	*NA*	*NA*	In *USP Reference Standards* <*11*>/USP Ropivacaine Related Compound A RS: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2,6-Dimethylaniline hydrochloride. $C_8H_{12}ClN$ 157.64 [CAS-21436-98-6]. to: 2,6-Dimethylaniline hydrochloride. $C_8H_{11}N \cdot HCl$ 157.64 AND In USP Ropivacaine Related Compound B RS: Change (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate. $C_{17}H_{26}N_2O$ 328.89

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate; (*R*)-*N*-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride monohydrate. $C_{17}H_{26}N_2O \cdot HCl \cdot H_2O$ 328.88
DESCRIPTION AND SOLUBILITY	REAGENTS AND REFERENCE TABLES/REFERENCE TABLES	*USP43–NF38*	6275	29-May-2020	1-Nov-2020	*NA*	*NA*	Change *Incommunicable Acid Hydrochloride*: to: *Aminolevulinic Acid Hydrochloride*:
ANHYDROUS	ASSAY/	*Harmonization*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DIBASIC CALCIUM PHOSPHATE	*Procedure*	*(Official December 01, 2019)*						Change *M* = actual molarity of the *Back-titrant* (mM/mL) to: *M* = actual molarity of the *Back-titrant* (mmol/mL) AND Change *F* = equivalency factor, 136.06 mg/mM to: *F* = equivalency factor, 136.06 mg/mmol
FILGRASTIM	ADDITIONAL REQUIREMENTS	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	Change *USP Reference Standards <11>* to: *USP Reference Standards <11>* USP Filgrastim RS
TRANYLCYPROMINE SULFATE	CHEMICAL INFORMATION	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	See https://www.usp nf.com/errata/tr anylcypromine-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sulfate-image for correction.
METOPROLOL SUCCINATE	*USP Reference standards <11>*	*USP43–NF38*	2917	29-May-2020	1-Jun-2020	*NA*	*NA*	In USP Metoprolol Related Compound C RS: Change (±)4-[2-Hydroxy-3-(1-methylethyl)aminopropoxy]benzaldehyde. $C_{13}H_{19}NO_3$ 237.29 to: 4-[2-Hydroxy-3-(isopropylamino)propoxy]benzaldehyde hydrochloride. $C_{13}H_{19}NO_3 \cdot HCl$ 273.76 AND In USP Metoprolol Related Compound D RS: Change (±) *N*,*N*-Bis[2-hydroxy-3-[4-(2-methoxy

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ethyl)phenoxy]propyl](1-methylethyl)amine. $C_{27}H_{41}NO_6$ 475.62 to: *N*,*N*-Bis{2-hydroxy-3-[4-(2-methoxyethyl)phenoxy]propyl}isopropylamine hydrochloride; also known as (±) *N*,*N*-Bis[2-hydroxy-3-[4-(2-methoxyethyl)phenoxy]propyl](1-methylethyl)amine hydrochloride. $C_{27}H_{41}NO_6$ · HCl 512.08
FILGRASTIM	ASSAY/*Potency*	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Standard solution*: Change 0.5 ng/mL of in *Medium B*. to: 0.5 ng/mL of USP Filgrastim

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS in *Medium B*. AND In *Positive control solution*: Change 10 ng/mL of in *Medium B* to: 10 ng/mL of USP Filgrastim RS in *Medium B*
ROPIVACAINE HYDROCHLORIDE INJECTION	*USP Reference standards <11>*	*USP43–NF38*	3945	29-May-2020	1-Jun-2020	*NA*	*NA*	In USP Ropivacaine Related Compound A RS: Change 2,6-Dimethylaniline hydrochloride. $C_8H_{12}ClN$ 157.64 [CAS-21436-98-6]. to: 2,6-Dimethylaniline hydrochloride. $C_8H_{11}N \cdot HCl$ 157.64 AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								In USP Ropivacaine Related Compound B RS: Change (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate. $C_{17}H_{26}N_2O$ 328.89 to: (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate; (*R)-N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride monohydrate. $C_{17}H_{26}N_2O \cdot HCl \cdot H_2O$ 328.88
DOXYCYCLINE CAPSULES	PERFORMANCE TESTS	*USP43–NF38*	1519	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Dissolution <711>*: Change *Test 2* to: *Test 2*: If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.
DOLASETRON MESYLATE	ASSAY/ *Procedure*	*USP43–NF38*	1483	29-May-2020	1-Jun-2020	*NA*	*NA*	Change *Mobile phase*: Acetonitrile, water, and 1 M ammonium formate (450:440:110), adding 0.19 mL of triethylamine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to the acetonitrile portion to: *Solution A*: Add 0.19 mL of triethylamine to each 450 mL of acetonitrile. *Mobile phase*: *Solution A*, water, and 1 M ammonium formate (450:440:110)
INDOMETHACIN SUPPOSITORIES	ASSAY/ *Procedure*	*Revision Bulletin (Official December 01, 2019)*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Chromatographic system*/ *Detector*: Change PDA (scan 200–600). to: PDA (scan 200–600 nm).
CARISOPRODOL	IMPURITIES/*Organic Impurities*	*USP43–NF38*	776	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Table 2*: Change Carisoprdol related compound A[a]

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OIL- AND WATER-SOLUBLE VITAMINS TABLETS	STRENGTH	*USP43–NF38*	5419	24-Apr-2020	1-May-2020	*NA*	*NA*	to: Carisoprodol related compound A[a] In the variable definition for *F* in *Vitamin E, Method 2/Analysis*: Change 1/2 for products labeled to contain *all-rac* vitamin E sources) to: 1/2 (for products labeled to contain *all-rac* vitamin E sources) AND In *Biotin, Method 2/Basal medium stock solution*: Change Dissolve the anhydrous dextrose and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								anhydrous Sodium acetate to: Dissolve the anhydrous dextrose and anhydrous sodium acetate AND In *Cyanocobalamin, Method 2/Basal medium stock solution*: Change thedextros, to: the dextrose, AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis*: Delete , calcium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 3/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Folic Acid, Method 3; Ascorbic Acid, Niacin or Niacinamide,*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Pyridoxine Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4/Analysis: Add ascorbic acid ($C_6H_8O_6$)
DIHYDROERGOTAMINE MESYLATE	*Assay*	*USP43–NF38*	1388	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Diluent 1*—Prepare a solution of 0.1 mL of phosphoric acid in 1000 mL of water. *Diluent 2*—Prepare a mixture of *Diluent 1* and acetonitrile (60:40). to: *Diluent 1*—Prepare a solution of 0.1 mL of phosphoric acid in 1000 mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								water.
GLYCERYL MONO AND DICAPRYLATE	IDENTIFICATION/*A. Fatty Acid Composition*	*USP43–NF38*	5794	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Standard solution 3*: Change USP Methyl Caproate RS, USP Methyl Caprylate RS, USP Methyl Caprate RS, USP Methyl Laurate RS, and USP Methyl Laurate RS. to: USP Methyl Caproate RS, USP Methyl Caprylate RS, USP Methyl Caprate RS, USP Methyl Laurate RS, and USP Methyl Myristate RS.
LEVONORDEFRIN	*Identification/B:*	*USP43–NF38*	2611	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Ultraviolet Absorption <197U>*— to: *Spectroscopic*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Identification Tests <197>, *Ultraviolet-Visible Spectroscopy*: 197U
0.002 M EDETATE DISODIUM VS	REAGENTS AND REFERENCE TABLES/*Solutions*	*USP43–NF38*	6240	24-Apr-2020	1-May-2020	*NA*	*NA*	Change 0.0744 g to: 0.744 g
PANTOPRAZOLE SODIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	3388	24-Apr-2020	1-May-2020	*NA*	*NA*	In USP Pantoprazole Related Compound ERS: Change $C_{34}H_{28}F_4N_6O_8S_2$ 764.74 to: $C_{32}H_{28}F_4N_6O_8S_2$ 764.72
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/*Dissolution <711>/Test 2*	*Revision Bulletin (Official October 01, 2019)*	Online	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Buffer stage medium*: Change Simulated gastric fluid, to: Simulated intestinal fluid,
RALTEGRAVIR TABLETS	ASSAY/*Procedure*	*USP43–NF38*	3834	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								M_{r1} = molecular weight of raltegravir, 444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
RALTEGRAVIR CHEWABLE TABLETS	IMPURITIES/*Organic Impurities*	*USP43–NF38*	3835	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir, 444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
CETIRIZINE HYDROCHLORIDE ORALLY DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	915	24-Apr-2020	1-May-2020	*NA*	*NA*	In USP Cetirizine Related Compound A RS: Change 506.98 to: 506.97
OIL-SOLUBLE VITAMINS TABLETS	STRENGTH	*USP43–NF38*	5356	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Vitamin E, Method 3*/*Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change alpha -ocopheryl acetate to: alpha-tocopheryl acetate
DEMECLOCYCLINE HYDROCHLORIDE	SPECIFIC TESTS/*Loss on Drying*	*USP43–NF38*	1248	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change Dry the *Sample* at 60° for 3 h. to: Dry the *Sample* in a capillary-stoppered bottle in vacuum at 60° for 3 h.
WATER-SOLUBLE VITAMINS WITH MINERALS TABLETS	STRENGTH	*USP43–NF38*	5552	24-Apr-2020	1-May-2020	*NA*	*NA*	In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1*/*Analysis*: Delete , calcium pantothenate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 3/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Folic Acid, Method 3; Ascorbic Acid, Niacin or Niacinamide, Pyridoxine*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4/Analysis: Add ascorbic acid ($C_6H_8O_6$),
EPINEPHRINE	ADDITIONAL REQUIREMENTS	*USP43–NF38*	Online	24-Apr-2020	1-May-2020	*NA*	*NA*	This erratum applies to the USP-NF ONLINE platform only. In *USP Reference Standards* <*11*>: Add USP Racepinephrine Hydrochloride RS
SODIUM METABISULFITE	IMPURITIES/*Limit of Chloride*	*USP43–NF38*	6020	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change (see *Nephelometry, Turbidimetry, and Visual Comparison* <855>). to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(see *Visual Comparison* <630>).
MEXILETINE HYDROCHLORIDE	CHEMICAL INFORMATION	*USP43–NF38*	2943	24-Apr-2020	1-May-2020	*NA*	*NA*	Change [5370-01-04]. to: [5370-01-4].
NEAR-INFRARED SPECTROSCOPY	4. VALIDATION AND VERIFICATION	*USP43–NF38*	7161	24-Apr-2020	1-May-2020	*NA*	*NA*	In *4.1 Validation/4.1.1 Accuracy/Validation criteria*/*Criteria 1*: Change Suitable agreement between SEP to: Suitable agreement between the standard error of prediction (SEP)
PROPRANOLOL HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	3746	24-Apr-2020	1-May-2020	*NA*	*NA*	In *System suitability*/*Suitability requirements*/*Relative standard deviation*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change NMT 5.0, to: NMT 5.0%,
RALTEGRAVIR CHEWABLE TABLETS	ASSAY/*Procedure*	*USP43–NF38*	3835	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir, 444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
VITAMIN E	ASSAY/*Alpha Tocopheryl Acid Succinate*	*USP43–NF38*	4637	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Sample solution*: Change tocoopheryl to: tocopheryl
REPOSITORY CORTICOTROPIN INJECTIONS	ADDITIONAL REQUIREMENTS	*USP43–NF38*	1174	24-Apr-2020	1-May-2020	*NA*	*NA*	In *USP Reference Standards* <*11*>: Add USP Ascorbic Acid RS
OIL- AND WATER-SOLUBLE VITAMINS	STRENGTH	*USP43–NF38*	5476	24-Apr-2020	1-May-2020	*NA*	*NA*	In the Calculate statement in *Niacin or*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
WITH MINERALS TABLETS								*Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 3/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Folic Acid Method 3; Ascorbic Acid, Niacin or Niacinamide, Pyridoxine Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4/Analysis*: Add ascorbic acid ($C_6H_8O_6$), AND In *Molybdenum, Method 2/Instrumental conditions*: Change (See *Atomic Absorption Spectroscopy <852>*.) to: (See *Ultraviolet-*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Visible Spectroscopy <*857*>.)
EPINEPHRINE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	1645	24-Apr-2020	1-May-2020	*NA*	*NA*	In the third calculation in the *Analysis*: Change C_U = concentration of Epinephrine in the *Sample solution* (mg/mL) to: C_U = concentration of Epinephrine in the *Sample solution* (µg/mL)
HEXYLENE GLYCOL	IMPURITIES/*Organic Impurities*	*USP43–NF38*	5814	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Any other individual impurity/Relative Response Factor* in *Table 2*: Change – to: 1.0
LOPERAMIDE HYDROCHLORIDE	IMPURITIES/*Organic*	*USP43–NF38*	2658	24-Apr-2020	1-May-2020	*NA*	*NA*	In *System suitability*/*Suitability*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Impurities							*re quire ments*/*Peak-to-valley ratio*: Change NLT 1.5 for loperamide related compounds G and H; NLT 1.5 for loperamide related compounds E and A, *System suitability solution* to: NLT 1.5 for loperamide *cis*-*N*-oxide and an hydroloperamide; NLT 1.5 for loperamide piperidinolamide and loperamide biphenyl analog, *System suitability solution*
0.02 M EDETATE	REAGENTS AND	*USP43–NF38*	6240	24-Apr-2020	1-May-2020	*NA*	*NA*	Change 0.7444 g

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DISODIUM VS	REFERENCE TABLES/*Solutions*							to: 7.444 g
POLYVINYL ALCOHOL	IDENTIFICATION/*A.*	*USP43–NF38*	3593	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Infrared Absorption* <197K> to: *Spectroscopic Identification Tests* <197>, *Infrared Spectroscopy*: 197K
RALTEGRAVIR TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	3834	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir, 444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
SACCHARIN SODIUM	SPECIFIC TESTS/*Readily Carbonizable Substances Test <271>*	*USP43–NF38*	3965	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Matching fluid A*: Change ferric chloride TS, to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ferric chloride CS,
BUDESONIDE	IM PUR ITIES/*Organic Impurities*	*USP43–NF38*	604	24-Apr-2020	1-May-2020	*NA*	*NA*	In footnote k in *Table 2*: Change 16?,17-[Butylidenebis(oxy)]-11?,21-dihydroxypregna-1,4-diene-3,20-dione-21-acetate. to: 16?,17-[Butylidenebis(oxy)]-11?-hydroxypregna-1,4-diene-3,20-dione-21-yl acetate.
OIL-SOLUBLE VITAMINS TABLETS	ADDITIONAL R EQUIREMENT S/*Labeling*	*USP43–NF38*	5356	24-Apr-2020	1-May-2020	*NA*	*NA*	In footnote 1: Change -alpha-tocopheryl to: *all-rac*-alpha-tocopheryl AND Change USP Vitamin E unit to: USP Vitamin E

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Unit AND Change 2*R* -alphatocopherol to: 2*R*-alpha-tocopherol
DEXAMETHASONE ACETATE	*Chromatographic purity*	*USP43–NF38*	1290	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Format buffer* to: *Formate buffer*
CAPRYLIC ACID	ASSAY/ *Procedure/ Chromatographic system*	*USP43–NF38*	5664	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Column*: Change 30-cm to: 30-m
LEUCOVORIN CALCIUM FOR INJECTION	ASSAY/ *Procedure/ Chromatographic system*	*USP43–NF38*	2569	24-Apr-2020	1-May-2020	*NA*	*NA*	Delete *Run time*: 2 times the retention time of the leucovorin peak
SUCROSE PALMITATE	IMPURITIES/*Inorganic Impurities*	*USP43–NF38*	6078	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Fats and Fixed Oils, Acid Value <401>*: Change NMT 6.0%, to: NMT 6.0,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NIACIN	IDENTIFICATION/*B.*	*USP43–NF38*	3138	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Ultraviolet Absorption* <197U> to: *Spectroscopic Identification Tests* <197>, *Ultraviolet-Visible Spectroscopy*: 197U

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- …
- Next page Next ›
- Last page Last »